REUTERS

Johnson & Johnson Announces World Health Organization to Review Ebola Vaccine Regimen

Johnson & Johnson (No. 8 on the DiversityInc Top 50 Companies list) announced that Janssen Vaccines & Prevention B.V. (Janssen) has completed a submission to the World Health Organization (WHO) for Emergency Use Assessment and Listing (EUAL) for its investigational preventive Ebola prime-boost vaccine regimen. The EUAL is a special procedure that can be implemented when there is an outbreak of a disease with high rates of morbidity or mortality and a lack of treatment or prevention options.


“Over the past four decades, we have seen 25 Ebola outbreaks, with the most recent in West Africa killing seven times more people than all previous outbreaks combined,” said Paul Stoffels, M.D., Chief Scientific Officer, Johnson & Johnson. “We must take action now so that a tragedy on the scale of West Africa never happens again. Having an Ebola vaccine available is critical for global preparedness. If the WHO grants an emergency use listing, this will accelerate the availability of Janssen’s investigational vaccine regimen to the international community in the event another Ebola crisis occurs.”

EUAL assists UN Member States and procurement agencies determine the acceptability for use of a specific vaccine in a public health emergency. The decision to grant EUAL to the investigational preventative vaccine regimen will be based on an evaluation of available data including quality, safety, and immunogenicity, as well as a risk/benefit analysis. While EUAL potentially allows for deployment of a vaccine in an emergency, the vaccine remains investigational pending formal regulatory agency review and approval.

The news coincides with the opening of the 8th International Symposium on Filoviruses in Antwerp, Belgium, hosted by the Antwerp Institute of Tropical Medicine, which is reviewing global progress against Ebola. The first outbreak of the disease was reported exactly 40 years ago, in September 1976 in Zaire (now the Democratic Republic of the Congo).

“Forty years after Ebola’s discovery, the potential availability of a durable prime-boost vaccine would be a tremendous achievement in global health,” said Johan Van Hoof, M.D., Global Therapeutic Area Head, Infectious Diseases and Vaccines, Janssen Pharmaceutical Companies, and a keynote speaker at the 8thInternational Symposium on Filoviruses. “If listed for emergency use, the investigational Janssen vaccine regimen could be a vital prevention tool for rapid outbreak response, particularly for health workers and vulnerable communities on the frontlines.”

Prime-boost vaccination is an established prevention approach for several infectious diseases. It involves giving an initial dose to prime the immune system, followed by a booster dose at a later date with the goal of potentially strengthening and optimizing the duration of immunity. Janssen’s heterologous prime-boost vaccine regimen contains two components based on AdVac technology from Janssen, and MVA-BN technology from Bavarian Nordic A/S.

The first clinical data for the investigational Janssen vaccine regimen among healthy volunteers were published in JAMA: The Journal of the American Medical Association in April 2016. The Phase 1 results from a UK study suggested that the regimen was well-tolerated and immunogenic (produced an immune response). The study found that 100 percent of study participants achieved an initial antibody response to Ebola, and that this was sustained eight months following vaccination among all volunteers.

The UK study provided the first set of data from a total of 10 clinical studies that are being conducted on a parallel track across the U.S., Europe and Africa in support of potential full licensure for a Janssen Ebola vaccine regimen. The first study of the vaccine regimen in a West African country affected by the Ebola epidemic began in Sierra Leone in October 2015.

Janssen is also preparing to initiate a first-in-human Phase 1 clinical study to test a second-generation, multivalent version of the AdVac/MVA-BN vaccine regimen. The multivalent heterologous prime-boost regimen is intended to protect against multiple filoviruses that cause disease in humans, including the Ebola, Sudan and Marburg viruses. The U.S. study will test the safety, tolerability and immunogenicity of this vaccine regimen in varying dosing schedules among healthy volunteers. The National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. National Institutes of Health (NIH), is funding this study. More information can be found at ClinicalTrials.gov.

Latest News

Tishaura Jones

Tishaura Jones Becomes Mayor of St. Louis, Joins Growing Number of Black Female Mayors Leading a Major American City

More and more Black women are becoming mayors of large American cities. Tishaura Jones has become the latest in a string of recent women candidates advancing to the top of city leadership. With her win on April 6, Jones becomes the first-ever Black woman mayor of St. Louis. Formerly the…

LinkedIn

Data From 500 Million LinkedIn Accounts Hacked and Put Up for Sale on the Dark Web

In a blow to businesspeople of all levels and industries, the career and business networking site LinkedIn confirmed that data “scraped” from approximately 500 million profiles has been archived by hackers and is being sold on the dark web. The site has approximately 675 million members, meaning that data from…

Abraham Lincoln High School

San Francisco School Board Forced to Abandon Controversial Plan to Rename Schools Honoring Historic Figures

The San Francisco Unified School District Board of Education drew nationwide attention earlier this year over its announcement to change the name of 44 schools “named after figures with disputed historical relevance.” And now, following widespread public condemnation and a vote of members, the board has decided it will no…

Park Cannon

Prosecutors Drop Charges Against Park Cannon, Georgia Representative Arrested For Protesting State’s New Racist Voter Restriction Laws

Reaction to Georgia’s restrictive and anti-Black voter disenfranchisement policies continues to stir up controversy. Major League Baseball pulled their wildly popular 2021 All-Star Game from Atlanta and moved it to Denver to show their disappointment with the decision. Georgia-based companies like Delta and Coca-Cola have also announced their disapproval of…

BASF Presents Roadmap to Climate Neutrality

Originally published at basf.com. BASF ranked No. 14 on The DiversityInc Top 50 Companies for Diversity list in 2020.   BASF is setting itself even more ambitious goals on its journey to climate neutrality and wants to achieve net-zero emissions by 2050. Based on the most recent progress in developing…